Monoamino oxidase A: An interesting pharmacological target for the development of multi-target QSAR

Mini-Reviews in Medicinal Chemistry

Volumn 12, Issue 10, 2012, Pages 947-958

  Molina, Enrique ^a,b   Sobarzo Sánchez, Eduardo ^b   Speck Planche, Alejandro ^b   Matos, Maria João ^b   Uriarte, Eugenio ^b   Santana, Lourdes ^b   Yáñez, Matilde ^b   Orallo, Francisco ^b  

^a UNIVERSIDAD DE CAMAGÜEY   (Cuba)

^b UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

Author keywords

Drug design; MAO A inhibitors; Monoamine oxidase; Multi target model; Neurodegenerative diseases; QSAR

Indexed keywords

2,3 DIHYDRO OXOISOAPORPHINE; 2,3,8,9,10,11 HEXAHYDROOXOISOAPORPHINE; AMINE OXIDASE (FLAVIN CONTAINING); AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; APORPHINE DERIVATIVE; BENZAMIDE; CLORGYLINE; COUMARIN; INDOLE; ISOAPORPHINE; MONOAMINE OXIDASE A INHIBITOR; OXOAPORPHINE; OXOISOAPORPHINE; PHENETHYLAMINE; RASAGILINE; THIOXANTHENE; UNCLASSIFIED DRUG;

ARTICLE; COMPUTER MODEL; CORRELATION COEFFICIENT; DRUG DESIGN; DRUG RECEPTOR BINDING; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; HYDROPHOBICITY; IC 50; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RECEIVER OPERATING CHARACTERISTIC;

ANIMALS; COMPUTER-AIDED DESIGN; DRUG DESIGN; HUMANS; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; NEURODEGENERATIVE DISEASES; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84866441979     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/138955712802762383     Document Type: Article

References (109)

1. Borges, F.; Roleira, F.; Milhazes, N.; Santana, L.; Uriarte, E. Simple coumarins and analogues in medicinal chemistry: occurrence, synthesis and biological activity. Curr. Med. Chem., 2005, 12, (8), 887-916.
2. Borges, F.R.F.; Milhazes, N.; Uriarte, E.; Santana, L., Simple Coumarins: Privileged Scaffolds in Medicinal Chemistry. Front. Med. Chem., 2009, 4, 23-85.
3. Delogu, G.; Picciau, C.; Ferino, G.; Quezada, E.; Podda, G.; Uriarte, E.; Vina, D. Synthesis, human monoamine oxidase inhibitory activity and molecular docking studies of 3-heteroarylcoumarin derivatives. Eur. J. Med. Chem., 2011, 46, (4), 1147-1152.
4. Matos, M.J.; Vina, D.; Picciau, C.; Orallo, F.; Santana, L.; Uriarte, E. Synthesis and evaluation of 6-methyl-3-phenylcoumarins as potent and selective MAO-B inhibitors. Bioorg. Med. Chem. Lett., 2009, 19, (17), 5053-5055.
5. Matos, M.J.; Vina, D.; Janeiro, P.; Borges, F.; Santana, L.; Uriarte, E. New halogenated 3-phenylcoumarins as potent and selective MAO-B inhibitors. Bioorg. Med. Chem. Lett., 2010, 20, (17), 5157-5160.
6. Binda, C.; Li, M.; Hubalek, F.; Restelli, N.; Edmondson, D.E.; Mattevi, A. Insights into the mode of inhibition of human mitochondrial monoamine oxidase B from high-resolution crystal structures. Proc. Natl. Acad. Sci. U.S.A., 2003, 100, (17), 9750-9755.
7. Binda, C.; Hubalek, F.; Li, M.; Edmondson, D.E.; Mattevi, A. Crystal structure of human monoamine oxidase B, a drug target enzyme monotopically inserted into the mitochondrial outer membrane. FEBS Lett., 2004, 564, (3), 225-228.
8. De Colibus, L.; Li, M.; Binda, C.; Lustig, A.; Edmondson, D.E.; Mattevi, A. Three-dimensional structure of human monoamine oxidase A (MAO A): relation to the structures of rat MAO A and human MAO B. Proc. Natl. Acad. Sci. U.S.A, 2005, 102, (36), 12684-12689.
9. Edmondson, D.E.; Mattevi, A.; Binda, C.; Li, M.; Hubalek, F. Structure and mechanism of monoamine oxidase. Curr. Med. Chem., 2004, 11, (15), 1983-1993.
10. Binda, C.; Hubalek, F.; Li, M.; Herzig, Y.; Sterling, J.; Edmondson, D.E.; Mattevi, A. Crystal structures of monoamine oxidase B in complex with four inhibitors of the Npropargylaminoindan class. J. Med. Chem., 2004, 47, (7), 1767-1774.
11. Shih, J.C. Cloning, after cloning, knock-out mice, and physiological functions of MAO A and B. Neurotoxicology, 2004, 25, (1-2), 21-30.
12. Schildkraut, J.J. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am. J. Psychiatry, 1965, 122, (5), 509-522.
13. Yamada, M.; Yasuhara, H. Clinical pharmacology of MAO inhibitors: safety and future. Neurotoxicology, 2004, 25, (1-2), 215-221.
14. Youdim, M.B.; Edmondson, D.; Tipton, K.F. The therapeutic potential of monoamine oxidase inhibitors. Nature reviews, 2006, 7, (4), 295-309.
15. Youdim, M.B. The advent of selective monoamine oxidase A inhibitor antidepressants devoid of the cheese reaction. Acta psychiatrica Scandinavica, 1995, 386, 5-7.
16. Rudorfer, M.V.; Potter, W.Z. Antidepressants. A comparative review of the clinical pharmacology and therapeutic use of the 'newer' versus the 'older' drugs. Drugs, 1989, 37, (5), 713-738.
17. Cesura, A.M.; Pletscher, A. The new generation of monoamine oxidase inhibitors. Progress in drug research. Fortschritte der Arzneimittelforschung, 1992, 38, 171-297.
18. Grimbergen, Y.A.; Langston, J.W.; Roos, R.A.; Bloem, B.R. Postural instability in Parkinson's disease: the adrenergic hypothesis and the locus coeruleus. Expert review of neurotherapeutics, 2009, 9, (2), 279-290.
19. Guay, D.R. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease. American journal of geriatric pharmacotherapy, 2006, 4, (4), 330-346.
20. Riederer, P.; Lachenmayer, L.; Laux, G. Clinical applications of MAO-inhibitors. Curr. Med. Chem., 2004, 11, (15), 2033-2043.
21. Henchcliffe, C.; Schumacher, H.C.; Burgut, F.T. Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors. Expert review of neurotherapeutics., 2005, 5, (6), 811-821.
22. Simuni, T.; Lyons, K.E.; Pahwa, R.; Hauser, R.A.; Comella, C.; Elmer, L.; Weintraub, D. Treatment of early Parkinson's disease. Part 2. European neurology, 2009, 61, (4), 206-215.
23. Gerlach, M.; Double, K.; Reichmann, H.; Riederer, P. Arguments for the use of dopamine receptor agonists in clinical and preclinical Parkinson's diseases. J. Neural Transm. Suppl., 2003, 167-193.
24. Palhagen, S.; Heinonen, E.; Hagglund, J.; Kaugesaar, T.; Maki-Ikola, O.; Palm, R. Selegiline slows the progression of the symptoms of Parkinson disease. Neurology, 2006, 66, (8), 1200-1206.
25. Youdim, M.B.; Fridkin, M.; Zheng, H. Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases. J. Neural. Transm., 2004, 111, (10/11), 1455-1471.
26. Riederer, P.; Danielczyk, W.; Grunblatt, E. Monoamine oxidase-B inhibition in Alzheimer's disease. Neurotoxicology, 2004, 25, (1/2), 271-277.
27. Ma, J.; Yoshimura, M.; Yamashita, E.; Nakagawa, A.; Ito, A.; Tsukihara, T. Structure of rat monoamine oxidase A and its specific recognitions for substrates and inhibitors. J. Mol. Bio., 2004, 338, (1), 103-114.
28. Gnerre, C.; Catto, M.; Leonetti, F.; Weber, P.; Carrupt, P.A.; Altomare, C.; Carotti, A.; Testa, B. Inhibition of monoamine oxidases by functionalized coumarin derivatives: biological activities, QSARs, and 3D-QSARs. J. Med. Chem., 2000, 43, (25), 4747-4758.
29. Vallejos, G.; Rezende, M.C.; Cassels, B.K. Charge-transfer interactions in the inhibition of MAO-A by phenylisopropylamines--a QSAR study. J. comput-aided Mol. Des., 2002, 16, (2), 95-103.
30. Di Santo, R.; Costi, R.; Roux, A.; Artico, M.; Befani, O.; Meninno, T.; Agostinelli, E.; Palmegiani, P.; Turini, P.; Cirilli, R.; Ferretti, R.; Gallinella, B.; La Torre F. Design, synthesis, and biological activities of pyrrolylethanoneamine derivatives, a novel class of monoamine oxidases inhibitors. J. Med. Chem, 2005, 48, (13), 4220-4223.
31. Mai, A.; Artico, M.; Esposito, M.; Ragno, R.; Sbardella, G.; Massa, S. Synthesis and biological evaluation of enantiomerically pure pyrrolyl-oxazolidinones as a new class of potent and selective monoamine oxidase type A inhibitors. Farmaco, 2003, 58, (3), 231-241.
32. Gallardo-Godoy, A.; Fierro, A.; McLean, T.H.; Castillo, M.; Cassels, B.K.; Reyes-Parada, M.; Nichols, D.E. Sulfur-substituted alpha-alkyl phenethylamines as selective and reversible MAO-A inhibitors: biological activities, CoMFA analysis, and active site modeling. J. Med. Chem., 2005, 48, (7), 2407-2419.
33. Hassan, S.Y.; Khattab, S.N.; Bekhit, A.A.; Amer, A. Synthesis of 3-benzyl-2-substituted quinoxalines as novel monoamine oxidase A inhibitors. Bioorg. Med. Chem. Lett., 2006, 16, 1753-1756.
34. Okamoto, Y.; Tanaka, S.; Kitayama, K.; Isomoto, M.; Masaishi, M. [Studies on the alkaloids of menispermaceous plants. CCLXI. Alkaloids of Menispermum dauricum DC. 8]. Yakugaku Zasshi, 1971, 91, (6), 684-687.
35. Kunitomo, J.; Satoh, M. Structure of menisporphine: a new type of isoquinoline alkaloid. Chem. Pharm. Bull., 1982, 30, 2659-2660.
36. Takani, M.; Takasu, Y.; Takahashi, K. Studies on constituents of medicinal plants. XXIII. Constituents of the vines of Menispermum dauricum DC. (2). Chem. Pharm. Bull., 1983, 31, 3091-3093.
37. Kunitomo, J.; Satoh, M.; Shingu, T. Structure and synthesis of menisporphine, a new type of isoquinoline alkaloid: Alkaloids of menispermum dauricum DC. (9). Tetrahedron, 1983, 39, 3261-3265.
38. Hu, S.M.; Xu, S.X.; Yao, X.S.; Cui, C.B.; Tezuka, Y.; Kikuchi, T. Dauricoside, a new glycosidal alkaloid having an inhibitory activity against blood-platelet aggregation. Chem. Pharm. Bull., 1993, 41, (10), 1866-1868.
39. Kunitomo, J.; Kaede, S.; Satoh, M. The structure of 2,3- dihydromenisporphine and the synthesis of dauriporphine, oxoisoaporphine alkaloids from Menispermum dauricum DC. Chem. Pharm. Bull., 1985, 33, 2778-2782.
40. Sugimoto, Y.; Babiker, H.A.; Inanaga, S.; Kato, M.; Isogai, A. Oxoisoaporphines from Menispermum dauricum. Phytochem. Rev., 1999, 52, 1431-1435.
41. Kunitomo, J.-I.; Miyata, Y. Further evidence for the structure of bianfugecine. Heterocycles, 1986, 24, 437-440.
42. Sobarzo-Sanchez, E.; De la Fuente, J.; Castedo, L. Synthesis and total assignment of 1H and 13C NMR spectra of new oxoisoaporphines by long-range heteronuclear correlations. Magn. Reson. Chem., 2005, 43, (12), 1080-1083.
43. Sobarzo-Sánchez, E.; Cassels, B.K.; Castedo, L. An expedient synthesis of unusual oxoisoaporphine and annelated quinoline derivatives. Synlett., 2003, 11, 1647-1650.
44. Carrieri, A.; Carotti, A.; Barreca, M.L.; Altomare, C. Binding models of reversible inhibitors to type-B monoamine oxidase. J. comput-aided mol. design, 2002, 16, (11), 769-778.
45. Tipton, K.F.; Boyce, S.; O'Sullivan, J.; Davey, G.P.; Healy, J. Monoamine oxidases: certainties and uncertainties. Curr. Med. Chem, 2004, 11, (15), 1965-1982.
46. Edmondson, D.E.; Binda, C.; Mattevi, A. Structural insights into the mechanism of amine oxidation by monoamine oxidases A and B. Arch. Biochem. Biophys., 2007, 464, 269-276.
47. Mevedev, A.E.; Veselovsky, A.V.; Shvedov, V.I.; Tikhonova, T.A.; Moskvitinia, T.A.; Fedotova, O.A.; Axenova, L.N.; Kamyshanskaya, A.Z.; Kirkel, A.Z.; Ivanov, A. Inhibition of monoamino oxidase by pirlindole analogues: 3D-QSAR and CoMFA analysis. J. Chem. Inf. Comput. Sci., 1998, 38, 1137-1144.
48. Chimenti, F.; Maccioni, E.; Secci, D.; Bolasco, A.; Chimenti, P.; Granese, A.; Befani, O.; Turini, P.; Alcaro, S.; Ortuso, F.; Cirilli, R.; La Torre, F.; Cardia, M.C.; Distinto, S. Synthesis, molecular modeling studies, and selective inhibitory activity against monoamine oxidase of 1-thiocarbamoyl-3,5-diaryl-4,5-dihydro- (1H)- pyrazole derivatives. J. Med. Chem., 2005, 48, (23), 7113-7122.
49. Harkcom, W.T.; Bevan, D.R. Molecular docking of inhibitors into monoamine oxidase B. Biochem. Biophys. Res. Commun., 2007, 360, 401-406.
50. Gallardo-Godoy, A.; Fierro, A.; McLean, T.H.; Castillo, M.; Cassels, B.K.; Reyes-Parada, M.; Nichols, D.E. Sulfur-Substituted R-Alkyl Phenethylamines as Selective and Reversible MAO-A Inhibitors: Biological Activities, CoMFA Analysis, and Active Site Modeling. J. Med. Chem., 2005, 48, 2407-2419.
51. Santana, L.; Uriarte, E.; Gonzalez-Diaz, H.; Zagotto, G.; Soto-Otero, R.; Mendez-Alvarez, E. A QSAR model for in silico screening of MAO-A inhibitors. Prediction, synthesis, and biological assay of novel coumarins. J. Med. Chem, 2006, 49, (3), 1149-1156.
52. Santana, L.; Gonzalez-Diaz, H.; Quezada, E.; Uriarte, E.; Yanez, M.; Vina, D.; Orallo, F. Quantitative structure-activity relationship and complex network approach to monoamine oxidase a and B inhibitors. J. Med. Chem., 2008, 51, (21), 6740-6751.
53. Zhao, J.; Kang, G.; Wang, W.; Zhao, M.; Zhang, X.; Lu, C.; Mao, W.; Chang, H.W.; Ye, W.; Peng, S. N-[2-chloro-9H-purin-6-yl]-Ncyclopropylglycylamino acids and derivatives: synthesis, evaluation as a class of novel analgesics, and 3D QSAR analysis. Bioorg. Med. Chem., 2009, 17, (17), 6305-6310.
54. Hansch, C.L.A. In: American Chemical Society, Washington, DC., 1995.
55. Kier, L.B.; Hall, L.H. Molecular connectivity in chemistry and drug research. Academic Press, New York., 1976.
56. Kier, L.B.; Hall, L.H. Molecular connectivity in structure-activity analysis. Research Studies Press, Wiley, Letchworth, Hertfordshire, England, New York., 1986.
57. García-Domenech, R.; García, F.J.; Soler, R.M.; Gálvez, J.; Anton-Fos, M.; de Julián-Ortiz, J.V. New analgesics design by molecular topology. Quant. Struc-Act. Rel., 1996, 15, 1-7.
58. de Julián-Ortiz, J.V.; Gálvez, J.; Muñoz-Collado, C.; García-Domenech, R.; Gimeno-Cardona, C. Virtual combinatorial synthesis and computational screening of new potential anti-herpes compounds. J. Med. Chem., 1999, 42, 3308-3314.
59. de Gregorio Alapont, C.; Garcia-Domenech, R.; Galvez, J.; Ros, M.J.; Wolski, S.; Garcia, M.D. Molecular topology: a useful tool for the search of new antibacterials. Bioorganic & medicinal chemistry letters, 2000, 10, (17), 2033-2036.
60. Gozalbes, R.; Brun-Pascaud, M.; Gálvez, J.; García-Domenech, R.; Girard, P.M.; Doucet, J.P.; Derouin, F. Prediction of quinolone activity against Mycobacterium avium by molecular topology and virtual computational screening. Antimicrob. Agents Chemother., 2000, 44, 2764-2770.
61. Todeschini, R.; Vighi, M.; Provenzani, R.; Finizio, A.; Gramatica, P. Modeling and prediction by using WHIM descriptors in QSAR studies: Toxicity of heterogeneous chemicals on Daphnia magna. Chemosphere, 1996, 32, 1527-1545.
62. Todeschini, R.; Vighi, M.; Finizio, A.; Gramatica, P. 3D-modelling and prediction by WHIM descriptors. Part 8. Toxicity and physicochemical properties of environmental priority chemicals by 2D-TI and 3D-WHIM descriptors. SAR and QSAR in environmental research, 1997, 7, (1/4), 173-193.
63. Zaliani, A.; Gancia, E. MS-WHIM scores for amino acids: A new 3D-description for peptide QSAR and QSPR studies. J. Chem. Inf. Comput. Sci., 1999, 39, 525-533.
64. Gancia, E.; Bravi, G.; Mascagni, P.; Zaliani, A. Global 3D-QSAR methods: MS-WHIM and autocorrelation. J. Comput-Aided Mol. Des., 2000, 14, 293-306.
65. Kubinyi, H. QSAR: Hansch analysis and related approaches. VCH, New York., 1993.
66. Kubinyi, H.; Kehrhahn, O.H. Quantitative structure-activity relationship. 1. The modified Free-Wilson approach. J. Med. Chem., 1976, 19, 578-586.
67. Kubinyi, H. Quantitative structure-activity relationships. 2. A mixed approach, based on Hansch and Free-Wilson analysis. J. Med. Chem., 1976, 19, 587-600.
68. Nunez, M.B.; Maguna, F.P.; Okulik, N.B.; Castro, E.A. QSAR modeling of the MAO inhibitory activity of xanthones derivatives. Bioorg. Med. Chem. lett., 2004, 14, (22), 5611-5617.
69. Todeschini, R.; Consonni, V. Handbook of Molecular Descriptors. Mannhold, R., Kubinyi, H., Timmerman, H., Eds.; Wiley-VCH: Weinheim, 2000.
70. Kier, L.B.; Hall, L.H. The Kappa indices for modeling molecular shape and flexibility in Topological Indices and Related Descriptors in QSAR and QSPR. Devillers, J., Balaban, A. T., Eds.; Gordon and Breach Science Publishers: Amsterdam, 1999, 445-489.
71. Estrada, E.; Uriarte, E.; Montero, A.; Teijeira, M.; Santana, L.; De Clercq E. A novel approach for the virtual screening and rational design of anticancer compounds. J. Med. Chem, 2000, 43, (10), 1975-1985.
72. http://www.ebi.ac.uk/chembldb/,C.D.b.A.a.
73. Speck, A.S.M.T.; García, A.; de Paulo Emerenciano, V.; Molina, E; Uriarte, E. Design of novel antituberculosis compounds using graph-theoretical and substructural approaches. Mol. Divers., 2009, 13, 445-458.
74. Viswanadhan, V.N.; Revankar, G.R.; Robins, R.K. Atomic physicochemical parameters for three dimensional structure directed quantitative structure-activity relationships. Part 4. Additional parameters for hydrophobic and dispersive interactions and their application for an automated superposition of certain naturally occurring nucleoside antibiotics. J. Chem. Info. Comput. Sci., 1989, 29, (3), 163-172.
75. Viswanadhan, V.N.R.M.R.; Bacquet, R. J.; Erion, M. D. Assessment of methods used for predicting lipophilicity: application to nucleosides and nucleoside bases. J. Comput. Chem., 1993, 14, 1019-1026.
76. Zagrovic, B.; van Gunsteren, W.F. Computational analysis of the mechanism and thermodynamics of inhibition of phophodiesterase 5A by synthetic ligands. J. Chem. Theory Comput., 2007, 3, 301-311.
77. Bren, U.; Martínek, V.; Florián, J. Free energy simulations of uncatalized DNA replication fidelity: structure and stability of T•G and dTTP•G terminal DNA mismatches flanked by a single dangling nucleotide. J. Phys. Chem. B, 2006, 110, 10557-10566.
78. Estrada, E. Modeling the diamagnetic susceptibilities of organic compounds by a substructural graph theoretical approach. J. Chem. Soc., Faraday Trans., 1998, 94, 1407-1411.
79. Estrada, E. Generalized spectral moments of the interacted line graph sequence. A novel approach to QSPR Studies. J. Chem. Inf. Comput. Sci., 1999, 39, 90-95.
80. Estrada, E.; Gutierrez, Y. Modeling chromatographic parameters by a novel graph theoretical sub-structural approach. J. Chromatogr. A, 1999, 858, (2), 187-199.
81. Estrada, E.; Uriarte, E. Quantitative structure--toxicity relationships using TOPS-MODE. 1. Nitrobenzene toxicity to Tetrahymena pyriformis. SAR QSAR. Environ. Res., 2001, 12, (3), 309-324.
82. Estrada, E.; Molina, E.; Uriarte, E. Quantitative structure-toxicity relationships using TOPS-MODE. 2. Neurotoxicity of a noncongeneric series of solvents. SAR QSAR Environ. Res., 2001, 12, (5), 445-459.
83. Estrada, E.; Peña, A. In silico studies for the rational discovery of anticonvulsant compounds. Bioorg. Med. Chem., 2000, 8, 2755-2770.
84. Perez Gonzalez, M.; Gonzalez Diaz, H.; Molina Ruiz, R.; Cabrera, M.A.; Ramos de Armas, R. TOPS-MODE based QSARs derived from heterogeneous series of compounds. Applications to the design of new herbicides. J. Chem. Inf. Comput. Sci., 2003, 43, (4), 1192-1199.
85. Estrada, E.; Uriarte, E. Recent advances on the role of topological indices in drug discovery research. Curr. Med. Chem., 2001, 8, (13), 1573-1588.
86. Estrada, E. Characterization of the folding degree of proteins. Bioinformatics, 2002, 18, (5), 697-704.
87. Estrada, E. Characterization of the amino acid contribution to the folding degree of proteins. Proteins, 2004, 54, (4), 727-737.
88. Estrada, E. Edge adjacency relationships and a novel topological index related to molecular volume. J. Chem. Info. Comput. Sci., 1995, 35, (1), 31-33.
89. Estrada, E. Spectral moments of the edge adjacency matrix in molecular graphs. Part 1. Definition and applications to the prediction of physical properties of alkanes. J. Chem. Inf. Comput. Sci., 1996, 36, (4), 844-849.
90. Estrada, E. Spectral moments of the edge-adjacency matrix of molecular graphs. Part 2. Molecules containing heteroatoms and QSAR applications. J. Chem. Inf. Comput. Sci., 1997, 37, (2), 320-328.
91. Estrada, E. Spectral moments of the edge adjacency matrix in molecular graphs. Part 3. Molecules containing cycles. J. Chem. Inf. Comput. Sci., 1998, 38, (1), 23-27.
92. Estrada, E.; Molina, E. Novel local (fragment-based) topological molecular descriptors for QSpr/QSAR and molecular design. J. Mol. Graph. Model, 2001, 20, (1), 54-64.
93. Estrada, E.; Molina, E.; Perdomo-Lopez, I. Can 3D structural parameters be predicted from 2D (topological) molecular descriptors? J. Chem. Inf Comput. Sci., 2001, 41, (4), 1015-1021.
94. Montero-Torres, A.; Vega, M.C.; Marrero-Ponce, Y.; Rolon, M.; Gomez-Barrio, A.; Escario, J.A.; Aran, V.J.; Martinez-Fernandez, A.R.; Meneses-Marcel, A. A novel non-stochastic quadratic fingerprints-based approach for the 'in silico' discovery of new antitrypanosomal compounds. Bioorg. Med. Chem., 2005, 13, (22), 6264-6275.
95. Marrero-Ponce, Y.; Iyarreta-Veitia, M.; Montero-Torres, A.; Romero-Zaldivar, C.; Brandt, C.A.; Avila, P.E.; Kirchgatter, K.; Machado, Y. Ligand-based virtual screening and in silico design of new antimalarial compounds using nonstochastic and stochastic total and atom-type quadratic maps. J. Chem. Inf. Model, 2005, 45, (4), 1082-1100.
96. Gonzalez Diaz, H.; Olazabal, E.; Castanedo, N.; Sanchez, I.H.; Morales, A.; Serrano, H.S.; Gonzalez, J.; de Armas, R.R. Markovian chemicals "in silico" design (MARCH-INSIDE), a promising approach for computer aided molecular design II: experimental and theoretical assessment of a novel method for virtual screening of fasciolicides. J. Mol. Mod., 2002, 8, (8), 237-245.
97. González-Díaz, H.; Sanchez, I.H.; Uriarte, E.; Santana, L. Symmetry considerations in Markovian chemicals 'in silico' design (MARCH-INSIDE) I: central chirality codification, classification of ACE inhibitors and prediction of sigma-receptor antagonist activities. Comput. Biol. Chem., 2003, 27, (3), 217-227.
98. Ramos de Armas, R.; Gonzalez Diaz, H.; Molina, R.; Uriarte, E. Markovian Backbone Negentropies: Molecular descriptors for protein research. I. Predicting protein stability in Arc repressor mutants. Proteins, 2004, 56, (4), 715-723.
99. Gonzalez-Diaz, H.; Prado-Prado, F.J.; Santana, L.; Uriarte, E. Unify QSAR approach to antimicrobials. Part 1: predicting antifungal activity against different species. Bioorg.Med. Chem, 2006, 14, (17), 5973-5980.
100. Prado-Prado, F.J.; Gonzalez-Diaz, H.; Santana, L.; Uriarte, E. Unified QSAR approach to antimicrobials. Part 2: predicting activity against more than 90 different species in order to halt antibacterial resistance. Bioorg. Med. Chem., 2007, 15, (2), 897-902.
101. Prado-Prado, F.J.; Gonzalez-Diaz, H.; de la Vega, O.M.; Ubeira, F.M.; Chou, K.C. Unified QSAR approach to antimicrobials. Part 3: first multi-tasking QSAR model for input-coded prediction, structural back-projection, and complex networks clustering of antiprotozoal compounds. Bioorganic & Med. Chem., 2008, 16, (11), 5871-5880.
102. Prado-Prado, F.J.; Martinez dela Vega, O.; Uriarte, E.; Ubeira, F.M.; Chou, K.C.; Gonzalez-Diaz, H. Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks. Bioorg. Med. Chem., 2009, 17, (2), 569-575.
103. Concu, R.; Dea-Ayuela, M.A.; Perez-Montoto, L.G.; Bolas-Fernandez, F.; Prado-Prado, F.J.; Podda, G.; Uriarte, E.; Ubeira, F.M.; Gonzalez-Diaz, H. Prediction of enzyme classes from 3D structure: a general model and examples of experimental-theoretic scoring of peptide mass fingerprints of Leishmania proteins. J. Proteome. Res, 2009, 8, (9), 4372-4382.
104. González-Díaz, H.; Munteanu, C.R. Topological Indices for Medicinal Chemistry, Biology, Parasitology, Neurological and Social Networks. Transworld Research Network, Trivandrum-695 023, Kerala, India., 2010.
105. van Waterbeemd, H. Discriminant analysis for activity prediction. In:. Manhnhold R, Krogsgaard-Larsen P, Timmerman H, Van Waterbeemd H (eds) Methods and principles in Medicinal Chemistry, Vol. 2, Chemometrics methods in molecular design. VCH, Weinhiem, 1995.
106. van Waterbeemd, H.M.R., Krogsgaard-Larsen, P., Timmerman, H., In: Chemometric Methods in Mol. Design. Method and Principles in Medicinal Chemistry;. Eds.; VCH: Weinhiem Ed., 1995; Vol. 2, pp 265-282.
107. Sobarzo-Sánchez, E.; Yañez-Jato, M.; Orallo Cambeiro, F.; Uriarte Villares, E.; Cano Rubio, E. Use of oxoisoaporphines and the derivatives thereof as selective inhibitors of monoamino oxidase A. PCT/ES2008/070114, 2009.
108. Fawcett, T. In: Technical report, Palo Alto. Laboratories, H., Ed.; USA, 2004.
109. Hanley, J.A.; McNeil, B.J. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology, 1982, 143, (1), 29-36.